Search

Your search keyword '"Christensen, S."' showing total 130 results

Search Constraints

Start Over You searched for: Author "Christensen, S." Remove constraint Author: "Christensen, S." Publisher elsevier bv Remove constraint Publisher: elsevier bv
130 results on '"Christensen, S."'

Search Results

1. EE215 Estimation of 10-Year Healthcare Costs of Patients Diagnosed With Myeloproliferative Neoplasms in Denmark

3. Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers

7. Intake design for an Atmosphere-Breathing Electric Propulsion System (ABEP)

9. Corrigendum to “SSP-27: 89Zr-immuno-PET of a novel bispecific amyloid β monoclonal antibody reveals improved and high specific brain uptake” [Nucl Med Biol (2020) Volumes 96–97, Supplement. S30-S31]

10. In-orbit aerodynamic coefficient measurements using SOAR (Satellite for Orbital Aerodynamics Research)

11. Gender Disparities in Philanthropic Fundraising by Academic Oncologists

18. Scaling up HCV-DAA treatment in patients on opioid substitution therapy (OST) – does alcohol and cannabis diminish cure rates? Data from the German Hepatitis C-Registry (DHC-R)

19. Significant changes of HCV patient characteristics over time in the era of direct antiviral agent therapy – are all HCV subpopulations treated similarly? – Results from the German hepatitis C Cohort

20. Can HCV be eliminated among HIV-infected MSM in Berlin? Modeling a setting with increasing incidence and high treatment rates

21. Has increased rollout of DAA therapy decreased the burden of late presentation and advanced liver disease in patients starting HCV therapy in Germany?

23. Does Sofosbuvir (SOF)/Velpatasvir (VEL) with or without Ribavirin (RBV) change the landscape of therapy in chronic hepatitis C genotype 3 (GT 3) infection? – Results from the GErman hepatitis C COhort (GECCO)

26. (421) A novel, non-opioid, conesnail peptide-based analgesic as a therapeutic alternative for the treatment of chronic pain

27. Ledipasvir/Sofosbuvir Treatment for 8 Weeks in Treatment-Naïve HCV Genotype 1 Infected Patients under Real Life Conditions: Data from the German Hepatitis C-Registry (DHC-R)

28. Treatment of Patients with Hepatitis C Virus (HCV) Genotype 3 Infection in the Era of Direct Acting Antivirals (DAA): Data from the German Hepatitis C-Registry (DHC-R)

30. Relapse and Treatment-Emergent RAVS with DAA-Based Regimens in Hepatitis C Virus (HCV) Mono- or Human Immunodeficiency Virus (HIV)-HCV Co-Infected Patients – a Real Concern in Clinical Practice? Results from the German Hepatitis C Cohort (GECCO)

40. P1149 PHYSICIAN ADHERENCE TO AND EFFICACY OF TRIPLE THERAPY WITH TELAPREVIR (TVR) PLUS PEGINTERFERON ALFA-2a/RIBAVIRIN (PEGIFN/RBV) IN A REAL-LIFE SETTING

41. P1148 BASELINE FACTORS ASSOCIATED WITH SUSTAINED VIROLOGIC RESPONSE (SVR) IN PATIENTS TREATED WITH FIRST GENERATION PROTEASE INHIBITORS PLUS PEGINTERFERON ALFA-2a (40KD) AND RIBAVIRIN

44. 830 CHOLESTEROL LEVELS AND PRESENCE OF DIABETES PREDICT EARLY VIROLOGICAL RESPONSE TO TRIPLE THERAPY WITH TELAPREVIR, PEG-INTERFERON alfa-2a 180 μg AND RIBAVIRIN IN CHRONIC HEPATITIS C

45. 805 WEEK 4 AND 12 EFFICACY OF TELAPREVIR (TVR) IN COMBINATION WITH PEGINTERFERON alfa 2a/RIBAVIRIN (P/R) IN TREATMENT EXPERIENCED PATIENTS WITH GT-1 UNDER REAL LIFE CONDITIONS

46. 871 REAL-WORLD EFFICACY AND SAFETY OF TELAPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY

47. PO-0953: Implementing IGRT in daily practice

Catalog

Books, media, physical & digital resources